These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor. Edmonson JH; Petersen IA; Shives TC; Mahoney MR; Rock MG; Haddock MG; Sim FH; Maples WJ; O'Connor MI; Gunderson LL; Foo ML; Pritchard DJ; Buckner JC; Stafford SL Cancer; 2002 Feb; 94(3):786-92. PubMed ID: 11857314 [TBL] [Abstract][Full Text] [Related]
3. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Steward WP; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E J Clin Oncol; 1993 Jan; 11(1):15-21. PubMed ID: 8418226 [TBL] [Abstract][Full Text] [Related]
4. Doxorubicin plus ifosfamide with rhGM-CSF in the treatment of advanced adult soft-tissue sarcomas: preliminary results of a phase II study from the EORTC Soft-Tissue and Bone Sarcoma Group. Steward WP; Verweij J; Somers R; Blackledge G; Clavel M; Van Oosterom AT; Greifenberg B; Soedirman J; Thomas D; Van Glabbeke M J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S193-7. PubMed ID: 1795008 [TBL] [Abstract][Full Text] [Related]
5. The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. Steward WP; Verweij J; Somers R; Spooner D; Kerbrat P; Clavel M; Crowther D; Rouesse J; Tursz T; Tueni E Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S241-4. PubMed ID: 8453707 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866 [TBL] [Abstract][Full Text] [Related]
7. The use of recombinant human granulocyte colony-stimulating factor in combination with single or fractionated doses of ifosfamide and doxorubicin in patients with advanced soft tissue sarcoma. Erkisi M; Erkurt E; Ozbarlas S; Burgut R; Doran F; Seyrek E J Chemother; 1996 Jun; 8(3):224-8. PubMed ID: 8808721 [TBL] [Abstract][Full Text] [Related]
8. Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. Okuno S; Petersen I; Shives T; Mahoney M; Haddock M; Sim F; O'Connor MI; Markovic SN; Maples W Am J Clin Oncol; 2016 Apr; 39(2):204-9. PubMed ID: 24487418 [TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. Edmonson JH; Ryan LM; Blum RH; Brooks JS; Shiraki M; Frytak S; Parkinson DR J Clin Oncol; 1993 Jul; 11(7):1269-75. PubMed ID: 8315424 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group Study. Pappo AS; Devidas M; Jenkins J; Rao B; Marcus R; Thomas P; Gebhardt M; Pratt C; Grier HE J Clin Oncol; 2005 Jun; 23(18):4031-8. PubMed ID: 15767644 [TBL] [Abstract][Full Text] [Related]
11. Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. Weh HJ; Zügel M; Wingberg D; Schwarz R; Zornig C; Dietel M; Hossfeld DK Onkologie; 1990 Dec; 13(6):448-52. PubMed ID: 2128712 [TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy of advanced bone and soft tissue sarcoma]. Yamawaki S; Isu K; Ubayama Y; Yamaguti H; Gotou M Gan To Kagaku Ryoho; 1984 Sep; 11(9):1757-63. PubMed ID: 6541020 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy of advanced sarcomas of bone and soft tissue. Antman KH Semin Oncol; 1992 Dec; 19(6 Suppl 12):13-20. PubMed ID: 1485169 [TBL] [Abstract][Full Text] [Related]
14. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365 [TBL] [Abstract][Full Text] [Related]
15. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS). Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM; Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685 [TBL] [Abstract][Full Text] [Related]
16. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT; Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapy of soft tissue sarcoma--a clinical evaluation of treatment over ten years. Wall N; Starkhammar H Acta Oncol; 2003; 42(1):55-61. PubMed ID: 12665332 [TBL] [Abstract][Full Text] [Related]
18. [Current strategy of chemotherapy for reflactory bone and soft tissue sarcomas]. Chuman H Gan To Kagaku Ryoho; 2004 Sep; 31(9):1331-9. PubMed ID: 15446552 [TBL] [Abstract][Full Text] [Related]
19. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890 [TBL] [Abstract][Full Text] [Related]
20. Efficacy of ifosfamide in combination with doxorubicin for the treatment of metastatic soft-tissue sarcoma. The Eastern Cooperative Oncology Group. Blum RH; Edmonson J; Ryan L; Pelletier L Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S238-40. PubMed ID: 8453706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]